Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 8/20 | 1.00 |
| ▸ | CD74 | P04233 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | POLB | P06746 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243468 | 0.88 | MIF (1.00) | MIFCD74KMT2APOLBMEN1 | |
| SCHEMBL18805679 | 0.86 | KMT2A (1.00) | MIFCD74KMT2APOLBMEN1 | |
| SCHEMBL18805676 | 0.86 | KMT2A (0.76) | MIFCD74KMT2APOLBMEN1 | |
| SCHEMBL13086565 | 0.85 | KMT2A (0.81) | MIFCD74KMT2APOLBMEN1 | |
| SCHEMBL29566285 | 0.85 | MIF (1.00) | MIFCD74KMT2APOLBMEN1 | |
| SCHEMBL18805692 | 0.85 | IDO1 (0.81) | MIFCD74KMT2APOLBMEN1 | |
| SCHEMBL2757836 | 0.85 | MIF (1.00) | MIFCD74KMT2APOLBMEN1 | |
| SCHEMBL20725151 | 0.83 | MIF (0.76) | MIFCD74KMT2APOLBMEN1 | |
| SCHEMBL2757851 | 0.83 | MIF (1.00) | MIFCD74KMT2APOLBMEN1 | |
| SCHEMBL14563196 | 0.83 | POLB (0.72) | MIFCD74KMT2APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2929882-B1 | MIF inhibitors | MIFCARE (FR) | 2018-06-13 | — | — | EP | disclosed |
| US-20170029387-A1 | MIF INHIBITORS | APAXEN (BE) | 2017-02-02 | — | — | US | disclosed |
| US-20170029387-A1 | MIF INHIBITORS | APAXEN (BE) | 2017-02-02 | — | — | US | disclosed |
| WO-2015155358-A1 | MIF INHIBITORS | MIFCARE (FR) | 2015-10-15 | — | — | WO | disclosed |
| EP-2929882-A1 | MIF inhibitors | Mifcare (FR) | 2015-10-14 | — | — | EP | disclosed |
| EP-0200345-A2 | Anti-allergic or anti-inflammatory substituted (hetero)-aralkylamino-ortho-phenols | BEECHAM GROUP PLC (GB) | 1986-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029387-A1 | MIF INHIBITORS | MIF, MSR1, MMP12 | MIF 1/4885CD74 23/4885KMT2A 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.